Expression of heparanase, Mdm2, and erbB2 in ovarian cancer

被引:0
|
作者
Ginath, S
Menczer, J
Friedmann, Y
Aingorn, H
Aviv, A
Tajima, K
Dantes, A
Glezerman, M
Vlodavsky, I
Amsterdam, A [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Holon & Sackler Fac Med, Edith Wolfson Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel
关键词
heparanase; Mdm2; erbB2; apoptosis; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the most lethal of gynecological malignancies. Yet early diagnosis and prognosis are far from being satisfactory. Degradation of heparan sulfate proteoglycans by heparanase appears to play an important role in the invasiveness of tumor cells through the basement membrane and into the extracellular matrix. Recent cloning of the heparanase gene and generation of monoclonal antibodies against the enzyme permit to examine tumor cell expression of the enzyme. The aim of the present study was to assess heparanase activity and localization in various subtypes of epithelial ovarian cancer in correlation with oncogene expression. Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 and Mdm2. Heparanase immunohistostaining and activity were present in mucinous carcinomas and were more intense than in endometrioid and in serous carcinomas. The lowest activity was observed in benign ovarian tumors and normal ovaries. In ovarian carcinomas the enzyme was intensely concentrated in the cytoplasm of the cancerous cells. In contrast, in normal ovaries and benign tumors the enzyme was predominantly localized in endothelial cells lining blood capillaries. The rate of apoptosis was considerably higher in mucinous and endometrioid carcinomas, and was lower in serous and primary peritoneal carcinomas. Extremely high concentration of heparanase was often demonstrated in apoptotic cells. Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. In benign ovarian tumors and normal ovaries the expression of both oncoproteins was extremely low. In conclusion ovarian carcinomas demonstrate higher levels of heparanase than benign tumors and normal ovaries suggesting that the enzyme may play an important role in metastatic spread of the cancerous cells. Apoptosis may be a significant part of the mechanism of the enzyme release into the extacellular space. Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [21] Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
    Yu, DH
    Hung, MC
    ONCOGENE, 2000, 19 (53) : 6115 - 6121
  • [22] Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
    Dihua Yu
    Mien-Chie Hung
    Oncogene, 2000, 19 : 6115 - 6121
  • [23] The Roles of MDM2 and MDMX in Cancer
    Karni-Schmidt, Orit
    Lokshin, Maria
    Prives, Carol
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11, 2016, 11 : 617 - 644
  • [24] MDM2 inhibitors for cancer therapy
    Vassilev, Lyubomir T.
    TRENDS IN MOLECULAR MEDICINE, 2007, 13 (01) : 23 - 31
  • [25] Mdm2 in growth signaling and cancer
    Levav-Cohen, Y
    Haupt, S
    Haupt, Y
    GROWTH FACTORS, 2005, 23 (03) : 183 - 192
  • [26] MDM2 AND MDMX IN CANCER AND DEVELOPMENT
    Marine, Jean-Christophe
    CANCER AND DEVELOPMENT, 2011, 94 : 45 - 75
  • [27] Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression
    Kim, Yeong Hwa
    Kim, Jang-Hee
    Choi, Yong Won
    Lim, Seo Kyung
    Yim, Hyunee
    Kang, Seok Yun
    Chung, Yong Sik
    Lee, Ga-Young
    Park, Tae Jun
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 94 (02) : 360 - 365
  • [28] Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
    Fernandez, Aileen, I
    Liu, Matthew
    Bellizzi, Andrew
    Brock, Jane
    Fadare, Oluwole
    Hanley, Krisztina
    Harigopal, Malini
    Jorns, Julie M.
    Kuba, M. Gabriela
    Ly, Amy
    Podoll, Mirna
    Rabe, Kimmie
    Sanders, Mary Ann
    Singh, Kamaljeet
    Snir, Olivia L.
    Soong, T. Rinda
    Wei, Shi
    Wen, Hannah
    Wong, Serena
    Yoon, Esther
    Pusztai, Lajos
    Reisenbichler, Emily
    Rimm, David L.
    JAMA ONCOLOGY, 2022, 8 (04) : 607 - 610
  • [29] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1094 - 1095
  • [30] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1094 - 1095